Susquehanna International Group, LLP Vista Gen Therapeutics, Inc. Transaction History

Susquehanna International Group, LLP

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 16, 2023	BUY	$0.12 - $0.3 $4,596 - $11,491	38,304 Added 46.74%	120,249 $14,000
Q4 2022 Feb 14, 2023	SELL	$0.09 - $0.16 $8,848 - $15,730	-98,314 Reduced 54.54%	81,945 $8,000
Q3 2022 Nov 14, 2022	BUY	$0.14 - $1.07 $4,786 - $36,583	34,190 Added 23.41%	180,259 $27,000
Q2 2022 Aug 15, 2022	BUY	$0.88 - $1.73 $17,996 - $35,380	20,451 Added 16.28%	146,069 $129,000
Q1 2022 May 16, 2022	SELL	$1.14 - $2.09 $151,898 - $278,479	-133,244 Reduced 51.47%	125,618 $156,000

Q4 2021 Feb 14, 2022	BUY	$1.67 - $2.76 $100,595 - $166,254	60,237 Added 30.33%	258,862 $504,000
Q3 2021 Nov 15, 2021	BUY	$2.62 - $3.45 $471,660 - $621,079	180,023 Added 967.76%	198,625 $544,000
Q2 2021 Aug 11, 2021	SELL	$1.96 - $3.15 $458,428 - $736,759	-233,892 Reduced 92.63%	18,602 $59,000
Q1 2021 May 17, 2021	BUY	$1.89 - $2.96 $477,213 - $747,382	252,494 New	252,494 $538,000
Q2 2020 Aug 14, 2020	SELL	$0.37 - $0.61 $7,323 - $12,074	-19,794 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$0.32 - $0.8 $1,956 - $4,890	6,113 Added 44.68%	19,794 $9,000
Q4 2019 Feb 14, 2020	SELL	$0.3 - $1.41 $144 - $676	-480 Reduced 3.39%	13,681 $9,000
Q3 2019 Nov 14, 2019	BUY	$0.46 - $1.29 $6,514 - $18,267	14,161 New	14,161 $15,000
Q3 2018 Nov 14, 2018	SELL	$1.23 - $1.49 $89,134 - $107,975	-72,467 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$0.85 - $1.5 $61,596 - $108,700	72,467 New	72,467 $99,000
Q1 2018 May 15, 2018	SELL	$0.91 - $1.73 $759,202 - $1.44 Million	-834,288 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$0.72 - $2.03 $600,687 - $1.69 Million	834,288	834,288 $926,000

2.7M

Ticker VTGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 206,836,000
Market Cap $720M
Description
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III d...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.